These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 9668334)

  • 1. 3,4-Diaminopyridine (DAP) in the treatment of Lambert-Eaton myasthenic syndrome (LEMS).
    Sanders DB
    Ann N Y Acad Sci; 1998 May; 841():811-6. PubMed ID: 9668334
    [No Abstract]   [Full Text] [Related]  

  • 2. 3,4-Diaminopyridine in Lambert-Eaton myasthenic syndrome and myasthenia gravis.
    Sanders DB; Howard JF; Massey JM
    Ann N Y Acad Sci; 1993 Jun; 681():588-90. PubMed ID: 8357206
    [No Abstract]   [Full Text] [Related]  

  • 3. [3,4-diaminopyridine in the treatment of myasthenic syndromes. Practical aspects].
    Vílchez JJ; Casanova B; Monte E
    Med Clin (Barc); 1996 Jan; 106(1):37-8. PubMed ID: 8750543
    [No Abstract]   [Full Text] [Related]  

  • 4. 3,4-Diaminopyridine, an orphan drug, in the symptomatic treatment of Lambert-Eaton myasthenic syndrome.
    Molgó J; Guglielmi JM
    Pflugers Arch; 1996; 431(6 Suppl 2):R295-6. PubMed ID: 8739381
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 3,4-Diaminopyridine for the treatment of myasthenia gravis with electrophysiological patterns of Lambert-Eaton myasthenic syndrome.
    Lee MK; Sunwoo IN; Kim SM
    J Clin Neurosci; 2018 Apr; 50():194-198. PubMed ID: 29402568
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 3,4-diaminopyridine treatment for Lambert-Eaton myasthenic syndrome in adults: a meta-analysis of randomized controlled trials.
    Zhang N; Hong D; Ouyang T; Meng W; Huang J; Li M; Hong T
    BMC Neurol; 2021 Sep; 21(1):371. PubMed ID: 34563155
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acute ventilatory failure in Lambert-Eaton myasthenic syndrome and its response to 3,4-diaminopyridine.
    Smith AG; Wald J
    Neurology; 1996 Apr; 46(4):1143-5. PubMed ID: 8780107
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment for Lambert-Eaton myasthenic syndrome.
    Keogh M; Sedehizadeh S; Maddison P
    Cochrane Database Syst Rev; 2011 Feb; 2011(2):CD003279. PubMed ID: 21328260
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Amifampridine phosphate (Firdapse(®)) is effective and safe in a phase 3 clinical trial in LEMS.
    Oh SJ; Shcherbakova N; Kostera-Pruszczyk A; Alsharabati M; Dimachkie M; Blanco JM; Brannagan T; Lavrnić D; Shieh PB; Vial C; Meisel A; Komoly S; Schoser B; Sivakumar K; So Y;
    Muscle Nerve; 2016 May; 53(5):717-25. PubMed ID: 26852139
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stimulated single-fiber electromyography in Lambert-Eaton myasthenic syndrome before and after 3,4-diaminopyridine.
    Sadeh M; River Y; Argov Z
    Muscle Nerve; 1997 Jun; 20(6):735-9. PubMed ID: 9149081
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of 3,4-diaminopyridine on the time course of decay of compound muscle action potential augmentation in the Lambert-Eaton myasthenic syndrome.
    Maddison P; Newsom-Davis J; Mills KR
    Muscle Nerve; 1998 Sep; 21(9):1196-8. PubMed ID: 9703446
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The myasthenic syndrome: anaesthesia in a patient treated with 3.4 diaminopyridine.
    Telford RJ; Hollway TE
    Br J Anaesth; 1990 Mar; 64(3):363-6. PubMed ID: 1970263
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Amifampridine for the Management of Lambert-Eaton Myasthenic Syndrome: A New Take on an Old Drug.
    Yoon CH; Owusu-Guha J; Smith A; Buschur P
    Ann Pharmacother; 2020 Jan; 54(1):56-63. PubMed ID: 31319693
    [No Abstract]   [Full Text] [Related]  

  • 14. Practical aspects of 3,4-diaminopyridine treatment of the Lambert-Eaton myasthenic syndrome.
    Lundh H; Nilsson O; Rosén I; Johansson S
    Acta Neurol Scand; 1993 Aug; 88(2):136-40. PubMed ID: 8213058
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment for Lambert-Eaton myasthenic syndrome.
    Maddison P; Newsom-Davis J
    Cochrane Database Syst Rev; 2003; (2):CD003279. PubMed ID: 12804456
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neurogenic bladder in Lambert-Eaton myasthenic syndrome and its response to 3,4-diaminopyridine.
    Satoh K; Motomura M; Suzu H; Nakao Y; Fujimoto T; Fukuda T; Nakane S; Nakamura T; Eguchi K
    J Neurol Sci; 2001 Jan; 183(1):1-4. PubMed ID: 11166786
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Palliative care for a patient with Lambert-Eaton myasthenic syndrome: role of 3,4-diaminopyridine.
    Chan KY; Chang RS; Lau VW; Chan ML; Lai T
    Ann Palliat Med; 2016 Oct; 5(4):311-314. PubMed ID: 27506750
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Treatment of Lambert-Eaton syndrome with 3,4- diaminopyridine and pyridostigmine].
    Yachachi Monfort A; Cortés Pastor F; de la Rubia Nieto A; Sánchez Garre MJ
    Farm Hosp; 2007; 31(4):254-6. PubMed ID: 18052623
    [No Abstract]   [Full Text] [Related]  

  • 19. 3,4-diaminopyridine for the treatment of Lambert-Eaton myasthenic syndrome.
    Wirtz PW; Titulaer MJ; Gerven JM; Verschuuren JJ
    Expert Rev Clin Immunol; 2010 Nov; 6(6):867-74. PubMed ID: 20979551
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiac arrest following an iatrogenic 3,4-diaminopyridine intoxication in a patient with Lambert-Eaton myasthenic syndrome.
    Boerma CE; Rommes JH; van Leeuwen RB; Bakker J
    J Toxicol Clin Toxicol; 1995; 33(3):249-51. PubMed ID: 7760450
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.